ABBVIE INC. |
Market Closed -
Other stock markets
|
After market 04:44:13 pm | |||
| 159.6 USD | -4.58% |
|
160 | +0.25% |
| 09:16pm | News Highlights : Top Company News of the Day - Friday at 3 PM ET | DJ |
| 07:15pm | News Highlights : Top Company News of the Day - Friday at 1 PM ET | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
167.3
USD
Average target price
184.1
USD
Spread / Average Target
+10.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.00% | 296B | |
| +25.83% | 653B | |
| +27.00% | 556B | |
| -6.76% | 354B | |
| +20.34% | 331B | |
| +13.09% | 233B | |
| +5.46% | 201B | |
| -9.61% | 193B | |
| -6.26% | 144B | |
| -11.77% | 143B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- AbbVie : Seeks FDA Approval for Crohn's Disease Treatment Candidate
